Keros Therapeutics (KROS) Liabilities and Shareholders Equity (2019 - 2026)

Keros Therapeutics (KROS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $338.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 45.12% year-over-year to $338.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 billion (up 22.78% YoY) and the FY2025 annual result came in at $338.0 million, down 45.12% from the prior year.
• Liabilities and Shareholders Equity eased to $338.0 million in Q4 2025, from $742.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $784.6 million in Q1 2025 to a low of $226.7 million in Q2 2022.
• A 5-year average of $410.2 million and a median of $347.2 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 325.35% — and 2025, when it plunged 45.12%.
• Tracing KROS's Liabilities and Shareholders Equity over 5 years: stood at $255.3 million in 2021, then rose by 20.19% to $306.8 million in 2022, then advanced by 20.62% to $370.0 million in 2023, then jumped by 66.44% to $615.9 million in 2024, then sank by 45.12% to $338.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025), per Business Quant data.